Symposium 2014: Limits to Tolerance of Increased RAS Signaling in Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Dr. Kevin Shannon, UCSF, describes how dominant oncogenes, Notch and KRAS, are down-regulated in drug-resistant leukemias.